While AI enables rapid drug creation for single individuals (n-of-1), the economic model is broken. It is not a commercial opportunity, creating an urgent societal challenge to develop new funding mechanisms like public-private partnerships to support these life-saving, non-scalable treatments.

By leveraging bulk purchasing, Gavi vaccinates children in developing countries for just $24 (compared to $1,300 in the US). This small investment saves one life for every 50-60 children vaccinated, yielding a cost-benefit ratio unmatched in healthcare or philanthropy.

To bridge its translational research gap, Japan’s Agency of Medical Research and Development offers a unique fund. For qualified startups, it matches every dollar of venture capital investment with two dollars of non-dilutive government funding, providing crucial capital to advance early-stage assets without giving up equity.

Renowned gene therapy pioneer Jim Wilson was forced to spin out ultra-rare disease programs into a new company after his initial venture failed to attract VC funding. This demonstrates that even elite scientific leadership cannot overcome investor disinterest in this segment without powerful, predictable government incentives like transferable priority review vouchers.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.

The standard patent system, which rewards innovation through high prices, is inefficient for creating products for the poor like vaccines. Advanced Market Commitments (AMCs) solve this by creating a pull mechanism: a legally binding promise to buy a large quantity at a set price, guaranteeing a market and aligning incentives for innovation.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

Diseases like Ebola and malaria, which primarily affect poor countries, lack market incentives for vaccine R&D. The Ebola vaccine only progressed because it was briefly on a U.S. bioterrorism list created after 9/11, highlighting how market failures require creative, sometimes accidental, incentives to overcome.

Unlike traditional UN agencies, Gavi operates as a public-private alliance. Its key innovation is not just fundraising but acting as a market-shaper. By guaranteeing consistent, large-scale purchases, Gavi gives private manufacturers the predictability needed to invest in capacity, ultimately lowering costs and ensuring supply security.